CD36 and coronary artery disorder: Furthermore, in the aorta, HFD + A treatment significantly downregulated the expression of adenylyl cyclase-associated protein 1 (CAP1), a human resistin receptor that increases the expression of CD36 mRNA, associated with coronary artery disease [60].